ClinicalTrials.gg

Program

tinengotinib

Also written as “TT-00420”, “TT-00420 (tinengotinib)” and “tinengotinib 10 mg QD plus darolutamide”.

Its studies are mostly in Cholangiocarcinoma · Prostatic Neoplasms · Breast Neoplasms · Carcinoma, Hepatocellular · Triple Negative Breast Neoplasms, led by 2 companies.

Furthest: phase 3, since Jun 29, 202311 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TransThera Sciences (Nanjing)105 open or runningphase 3since Jun 29, 2023Aug 21, 2018Dec 2026phase 3 · NCT05948475
Akeso11 open or runningphase 2since Jun 26, 2025Jun 26, 2025May 10, 2027phase 2 · NCT07052253

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2018First study: phase 1 study in Triple Negative Breast NeoplasmsNew to TransThera Sciences (Nanjing)TransThera Sciences (Nanjing) · NCT03654547 · 48 enrolled · United States, China
  2. Jan 6, 2021Phase 1 study in HealthyTransThera Sciences (Nanjing) · NCT04705922 · 24 enrolled · United States
  3. Feb 2, 2021Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT04742959 · 203 enrolled · United States
  4. May 27, 2021Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT04919642 · 55 enrolled · United States
  5. Jan 26, 2022Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05253053 · 84 enrolled · China
  6. Jun 29, 2023Phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05948475 · 200 enrolled · United States, Austria, Belgium and more
  7. Sep 5, 2023Phase 2 study in Cholangiocarcinoma MetastaticTransThera Sciences (Nanjing) · NCT06057571 · 50 enrolled · China
  8. Jun 26, 2025Akeso's first study: phase 2 study in Carcinoma, HepatocellularNew to AkesoAkeso · NCT07052253 · 100 planned · China
  9. Dec 26, 2025Phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT07328919 · 138 planned · China
  10. Mar 19, 2026Phase 2 study in Breast NeoplasmsTransThera Sciences (Nanjing) · NCT07498478 · 94 planned · China
  11. Oct 3, 2026Phase 2 study in Prostatic NeoplasmsTransThera Sciences (Nanjing) · NCT07871110 · 182 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05948475
  2. May 10, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularAkeso · NCT07052253
  3. Jun 30, 2027Primary completion: phase 2 study in Breast NeoplasmsTransThera Sciences (Nanjing) · NCT07498478
  4. Dec 31, 2028Primary completion: phase 2 study in Prostatic NeoplasmsTransThera Sciences (Nanjing) · NCT07871110

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07871110Prostatic Neoplasms · China2RecruitingTransThera Sciences (Nanjing)Dec 31, 2028182
NCT07498478Breast Neoplasms · China2RecruitingTransThera Sciences (Nanjing)Jun 30, 202794
NCT07328919Cholangiocarcinoma · China3Not yet recruitingTransThera Sciences (Nanjing)Dec 31, 2029138
NCT07052253Carcinoma, Hepatocellular · China2RecruitingAkesoMay 10, 2027100
NCT06057571Cholangiocarcinoma Metastatic · China2Active, not recruitingTransThera Sciences (Nanjing)Jul 27, 202550
NCT05948475Cholangiocarcinoma · United States, Austria, Belgium and more3Active, not recruitingTransThera Sciences (Nanjing)Dec 2026200
NCT05253053Cholangiocarcinoma · China2CompletedTransThera Sciences (Nanjing)Aug 31, 202484
NCT04919642Cholangiocarcinoma · United States2CompletedTransThera Sciences (Nanjing)Feb 28, 202455
NCT04742959Cholangiocarcinoma · United States2CompletedTransThera Sciences (Nanjing)Feb 20, 2024203
NCT04705922Healthy · United States1CompletedTransThera Sciences (Nanjing)Mar 7, 202124
NCT03654547Triple Negative Breast Neoplasms · United States, China1CompletedTransThera Sciences (Nanjing)Jan 31, 202348

How it is read

Names in the registry

  • “TT-00420”, 4 entries
  • “TT-00420 (tinengotinib)”, 3 entries
  • “tinengotinib 10 mg QD plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD plus enzalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.